文献速递消化系统肿瘤

瑞戈非尼联合伊匹木单抗与纳武利尤单抗治疗难治性微卫星稳定非肝转移性结直肠癌的更新生存结局:一项Ⅰ期非随机临床试验

Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial.
PubMed 文献 · Eur J Cancer · 2024-11-02

在39例难治性微卫星稳定(MSS)转移性结直肠癌患者中评估瑞戈非尼联合伊匹木单抗与纳武利尤单抗(RIN)方案,其中22例非肝转移(NLM)患者在推荐Ⅱ期剂量(RP2D)下治疗,客观缓解率(ORR)为36.4%(8/22),中位随访42个月,中位总生存期(OS)为27.5个月,3例缓解者在治疗完成后无病生存超过18个月。

要点

  • NLM队列RP2D水平ORR为36.4%(8/22),中位PFS为5.0个月。
  • 中位随访42个月,1年、2年、3年PFS率分别为24.1%、24.1%、19.3%。
  • 中位OS为27.5个月,3例缓解者治疗完成后无病生存超过18个月。

核心结论

  • 延长随访后,RIN联合治疗在部分NLM MSS转移性结直肠癌患者中显示出持久临床获益,包括3例缓解者在治疗完成后无病生存超过18个月、可能治愈。

研究设计与样本

  • Ⅰ期非随机临床试验(NCT04362839),2020年5月至2022年1月入组39例难治性MSS转移性结直肠癌患者,接受RIN治疗直至进展、不可接受毒性或满2年完成治疗,主要终点为RP2D选择。

主要发现

  • 22例难治性NLM MSS结直肠癌患者在RIN的RP2D水平接受治疗,ORR为36.4%(8/22),中位PFS为5.0个月(95%CI:3-9)。
  • 中位随访42个月,按RECIST标准1年、2年、3年PFS率分别为24.1%、24.1%、19.3%。
  • 中位OS为27.5个月(95%CI:14.0至NE),数据截止时6例患者仍有持续临床获益,包括3例缓解者治疗完成后无病生存超过18个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Combination regorafenib, ipilimumab, and nivolumab (RIN) was evaluated in a phase 1 nonrandomized study (NCT04362839) of refractory microsatellite stable (MSS) metastatic colorectal cancer. Promising antitumor activity was previously reported in the non-liver metastatic (NLM) population. This updated analysis describes long-term survival outcomes in the NLM cohort and highlights durable remissions with potential cure following completion of RIN therapy. METHODS: Between May 2020 and January 2022, 39 patients with refractory MSS metastatic colorectal cancer were enrolled. Patients received RIN until progression, unacceptable toxicity, or completion at two years. The primary endpoint was recommended phase 2 dose (RP2D) selection. Secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS) and overall survival (OS) at the RP2D level. RESULTS: 22 patients with refractory non-liver metastatic MSS colorectal cancer were treated at the RP2D of RIN. ORR was 36.4 % (8/22 patients), and median PFS was 5.0 months (95 % CI: 3-9). After a median follow-up of 42 months, the 1-, 2-, and 3-year PFS rates were 24.1 %, 24.1 %, and 19.3 % by RECIST. The median OS was 27.5 months (95 % CI: 14.0 to NE). At data cutoff, 6 patients had ongoing clinical benefit, including 3 responders who remain disease-free > 18 months after treatment completion. CONCLUSION: With extended follow-up, RIN combination therapy demonstrated durable clinical benefit in a subset of patients with NLM MSS metastatic colorectal cancer, including potential cure in 3 responders who remain disease-free > 18 months after treatment completion.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Xiao A, Li X, Wang C, et al. Updated survival outcome of regorafenib, ipilimumab, and nivolumab in refractory microsatellite stable non-liver metastatic colorectal cancer: A phase I nonrandomized clinical trial. Eur J Cancer. 2024. PMID: 39504677. doi:10.1016/j.ejca.2024.115111

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。